MaxCyte (NASDAQ:MXCT – Get Free Report) and Quantum-Si (NASDAQ:QSI – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.
Valuation and Earnings
This table compares MaxCyte and Quantum-Si”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MaxCyte | $33.03 million | 3.91 | -$44.63 million | ($0.33) | -3.79 |
| Quantum-Si | $2.44 million | 124.69 | -$101.34 million | ($0.46) | -3.02 |
Risk and Volatility
MaxCyte has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Quantum-Si has a beta of 3.21, meaning that its share price is 221% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings for MaxCyte and Quantum-Si, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MaxCyte | 1 | 1 | 1 | 0 | 2.00 |
| Quantum-Si | 1 | 1 | 2 | 0 | 2.25 |
MaxCyte presently has a consensus target price of $5.00, suggesting a potential upside of 300.00%. Quantum-Si has a consensus target price of $2.50, suggesting a potential upside of 79.86%. Given MaxCyte’s higher possible upside, equities analysts plainly believe MaxCyte is more favorable than Quantum-Si.
Profitability
This table compares MaxCyte and Quantum-Si’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MaxCyte | -114.77% | -18.92% | -16.14% |
| Quantum-Si | -6,138.26% | -47.12% | -43.18% |
Insider & Institutional Ownership
68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 39.9% of Quantum-Si shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by insiders. Comparatively, 22.0% of Quantum-Si shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
MaxCyte beats Quantum-Si on 8 of the 14 factors compared between the two stocks.
About MaxCyte
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
About Quantum-Si
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
